✦ LIBER ✦

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

✍ Scribed by Jae Hoon Lee; Dong Soon Lee; Je Jung Lee; Yoon Hwan Chang; Jong Youl Jin; Deog-Yeon Jo; Soo Mee Bang; Hyo Jung Kim; Jin Seok Kim; Kihyun Kim; Hyeon Seok Eom; Chang Ki Min; Sung Soo Yoon; Sun Hee Kim; Cheolwon Suh; Kyung Sam Cho; the Korean Multiple Myeloma Working Party (KMMWP)

Book ID: 107619067
Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 191 KB
Volume: 92
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0617-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of physicians’ perspectives ver

Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma

✍ Axel C. Mühlbacher; Matthias Nübling 📂 Article 📅 2010 🏛 Springer 🌐 French ⚖ 384 KB

Light chain isotype-associated suppressi

Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma

✍ R. C. F. Leonard; Professor I. C. M. MacLennan; Y. Smart; R. I. Vanhegan; J. Cuz 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 French ⚖ 743 KB

## Abstract The number of plasma cells in the lamina propria of the gut has been assessed in patients with multiple myeloma and other B‐cell neoplasms. The total number of these plasma cells was reduced in most patients with myelomatosis and one‐third of patients with lymphoplasmacytoid tumours. Th

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Soluble syndecan-1 level at diagnosis is

Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

✍ Richard Lovell; Janet A. Dunn; Gulnaz Begum; Nicola J. Barth; Tim Plant; Paul A. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Abnormalities of chromosome 1p/q are hig

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

✍ Ka Lung Wu; Berna Beverloo; Henk M. Lokhorst; Christine M. Segeren; Bronno Van D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB